HAL Allergy is one of the European top players in the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. With a highly competitive product portfolio, including subcutaneous and sublingual products, and a future-oriented pipeline portfolio, HAL Allergy strives to provide the best possible medical products and scientific output. HAL Allergy is located in the Bio Science Park in Leiden, The Netherlands.